Clarinaze learning scenario

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer Plc. on 0118 2063500.

Clarinaze^® Allergy Control 0.05% nasal spray(0.05% mometasone furoate). Indications: Symptoms of seasonal or perennial allergic rhinitis in adults aged 18 years. Dosage and administration: Two actuations (50mcg/actuation) in each nostril once daily (total dose 200 mcg). Once symptoms are controlled, dose reduction to one actuation in each nostril (total dose 100 mcg). Product requires initial priming prior to first use. Contraindications: Hypersensitivity to any of the ingredients, presence of untreated localised infection of the nasal mucosa (e.g. herpes simplex), recent nasal surgery or trauma where healing has not yet occurred. Warnings and precautions: Treatment should be stopped and medical advice sought if no improvement is seen in 14 days. Do not use for >3 months without consulting a doctor. Use with caution in patients with: active or quiescent tuberculosis, untreated fungal, bacterial, or systemic viral infections. Potentially immunosuppressed patients receiving corticosteroids should be warned of risk of infections (e.g. chickenpox, measles) and of the importance of obtaining medical advice if such exposure occurs. Patients on treatment over several months should be examined periodically for changes in nasal mucosa. Product contains benzalkonium chloride which may cause irritation or swelling inside the nose. Treatment is not recommended in patients with nasal septum perforation. Systemic effects of nasal corticosteroids may occur. Instances of increased intraocular pressure have been reported. Patients transferred from long-term administration of systemically active corticosteroids require careful attention. Side effects: Epistaxis, pharyngitis, upper respiratory tract infection, headache, nasal burning, nasal irritation, nasal ulceration, throat irritation. Pregnancy: No or limited data are available, treatment not recommended unless potential benefit to mother justifies potential risk. RRP (Excl. VAT): £11.66 – 140 actuations. MA number: PL 00010/0663 MA holder: Bayer plc, 400 South Oak Way, Reading, RG2 6AD, UK. Legal category: P. Date of preparation: October 2018.

Clarityn Allergy 10mg Tablets & Clarityn Rapide Allergy 10mg Tablets (loratadine) are indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria. Dosage and administration: Adults, elderly and children aged 12 years and over: One tablet once daily. Children 2 to 12 years of age - Bodyweight more than 30kg: 10mg once daily (one tablet once daily). Bodyweight 30kg or less: Not recommended. Contraindications: Hypersensitivity to the active substances or to any other ingredients. Warnings and precautions: In severe liver impairment, patients should be given lower initial dose as they may have reduced loratadine clearance: an initial dose of 10mg every other day is recommended for adults and children weighing more than 30kg. Clarityn should be discontinued at least 48 hours before skin tests. Clarityn 10mg Tablets - Clarityn contains lactose; thus patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Side effects: Very rarely hypersensitivity reactions (including angioedema and anaphylaxis), dizziness, convulsion, tachycardia, palpitation, nausea, dry mouth, gastritis, abnormal hepatic function, rash, alopecia and fatigue. In adults and adolescents, most frequently, somnolence, headache, increased appetite and insomnia were reported. In children (2 to 12 years of age), headache, nervousness and fatigue were most common. Use in pregnancy and breast-feeding: Preferable to avoid during pregnancy. Clarityn should not be used during breast-feeding. RRP (Excl. VAT): 10mg Tablets - 7's £4.19; 14's £6.29; 30's £9.64; 60's £15.99. Rapide Tablets - 10's £4.99. MA numbers: PL 00010/0655, PL 00010/0657 & PL 00010/0662. MA holder: Bayer plc, 400 South Oak Way, Reading, RG2 6AD. Legal category: GSL & P (60's). Date of preparation: February 2019.

1. https://www.england.nhs.uk/wp-content/uploads/2018/03/otc-guidance-for-ccgs.pdf

2. https://cks.nice.org.uk/allergic-rhinitis#!scenario

References last accessed March 2020